British pharmaceutical giant AstraZeneca has made known a US$1.5 billion investment in a new Production facility in Singapore. This plant will specialize in making antibody-drug conjugates (ADCs) and targeted cancer therapies, marking a significant expansion of AstraZeneca's global manufacturing capacity. The report, made on Monday, May 20, highlights the company's dedication to increasing its supply chain and production operations.